类风湿关节炎患者利妥昔单抗治疗后低丙种球蛋白血症不罕见且与良好应答相关:13年真实世界经验
基线IgG和IgM水平分别预测低IgG和低IgM发生,低IgM与更好的疾病控制相关,且低丙种球蛋白血症未增加严重感染率。
要点
- 利妥昔单抗治疗RA患者中43.4%出现低丙种球蛋白血症,低IgG和低IgM分别占24.1%和31.3%。
- 低IgM与更低的DAS28及更高缓解率相关,低IgG则无此关联。
- 低丙种球蛋白血症未增加严重感染发生率。
核心结论
- 利妥昔单抗治疗的RA患者中低丙种球蛋白血症发生率约43%,低IgM但非低IgG与更好的疾病结局相关,且未增加严重感染。
主要发现
- 43.4%出现任何低丙种球蛋白血症,24.1%出现低IgG,31.3%出现低IgM。
- 基线IgG水平较低预测低IgG发生,基线IgM水平较低预测低IgM发生。
- 低IgM患者DAS28(CRP)更低、缓解率和低疾病活动度更高,而维持正常IgG者更常使用甲氨蝶呤。
- 各亚组间严重感染率无差异。
临床怎么用
- 接受利妥昔单抗治疗的RA患者应监测免疫球蛋白水平,基线IgG和IgM较低者更易出现相应降低。
- 出现低IgM可能提示更好的疾病应答,但需结合临床综合判断。
- 低丙种球蛋白血症未增加严重感染风险,无需因此常规调整治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rituximab (RTX) use in the treatment of RA can be complicated by decrease in IgG, IgM or IgA levels (hypogammaglobulinemia-HGG). The aim of this study was to define the frequency of HGG in RA patients treated with RTX and to identify associations between its occurrence and patients' characteristics, disease outcomes and serious infections rate. METHODS: RA patients treated with RTX in two rheumatology centers from January 2007 to January 2020 were retrospectively examined. Demographical, clinical and laboratory parameters were recorded at baseline and at last visit. RESULTS: Eighty-three patients (84.3% females) with a mean age of 63.2 years were enrolled. They had baseline DAS28(CRP) of 5.2 (1.1) and received a median (range) of 8 (2-20) RTX cycles. A total of 43.4%, 24.1% and 31.3% developed 'any HGG', 'low IgG' and 'low IgM', respectively. Lower baseline IgG and IgM levels were predictors of 'low IgG' and 'low IgM' occurrence, respectively. Patients who developed 'low IgM' exhibited lower DAS28(CRP) and increased rates of remission and low disease activity compared with those with normal IgM levels. Patients who maintained normal IgG were receiving methotrexate more frequently. No differences were observed in serious infections rate among subgroups. CONCLUSION: HGG occurred in 43% of RTX-treated patients. Patients who developed low IgG or low IgM had lower baseline levels than those who did not. Concomitant DMARD and corticosteroid therapy was not associated with HGG. Low IgM, but not low IgG, development was associated with better disease outcomes. HGG was not associated with an increased incidence of serious infections.
引用
- Evangelatos G, Fragoulis GE, Klavdianou K, et al. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology (Oxford). 2021. PMID: 33175958. doi:10.1093/rheumatology/keaa617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。